CKB BOOST now has AMP/CAP/ASCO evidence level coding!
CKB CORE brings back EGFR, PIK3CA, removes BRCA1, BRCA2, KRAS, and offers new content with DDR2.
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.